WO2009113704A3 - Composé contenant du fluor et procédé de détection de biomplécule l'utilisant - Google Patents

Composé contenant du fluor et procédé de détection de biomplécule l'utilisant Download PDF

Info

Publication number
WO2009113704A3
WO2009113704A3 PCT/JP2009/054984 JP2009054984W WO2009113704A3 WO 2009113704 A3 WO2009113704 A3 WO 2009113704A3 JP 2009054984 W JP2009054984 W JP 2009054984W WO 2009113704 A3 WO2009113704 A3 WO 2009113704A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluorine
group
containing compound
substituted
same
Prior art date
Application number
PCT/JP2009/054984
Other languages
English (en)
Other versions
WO2009113704A2 (fr
Inventor
Fumio Yamauchi
Itaru Hamachi
Takashi Sakamoto
Original Assignee
Kyoto University
Canon Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University, Canon Kabushiki Kaisha filed Critical Kyoto University
Publication of WO2009113704A2 publication Critical patent/WO2009113704A2/fr
Publication of WO2009113704A3 publication Critical patent/WO2009113704A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D259/00—Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

L'invention concerne un composé contenant du fluor amphiphile ayant une structure représentée par la formule générale (1) suivante comportant un ligand hydrophile RI, une sonde fluorée Rf, et des lieurs L1 et L2. Dans cette formule, RI représente un ligand hydrophile ayant un groupe polaire; L2 représente un groupe alkylène ayant un ou plusieurs -CH2- qui peuvent être indépendamment substitués par l'un ou l'autre des -NH-, -O-, -CO-, -SO2-, et un groupe arylène; Rf est sélectionné dans un groupe alkyle qui a un ou plusieurs atomes d'hydrogène substitués par un atome de fluor, et dans un groupe aryle ayant au moins un atome d'hydrogène substitué par un atome de F et un groupe perfluoroalkyle; m est sélectionné entre 0 et 1; et n entre 0 et 1. Un agrégat comprenant les composés est destabilisé par le biais de la liaison à un enzyme.
PCT/JP2009/054984 2008-03-11 2009-03-10 Composé contenant du fluor et procédé de détection de biomplécule l'utilisant WO2009113704A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008-061849 2008-03-11
JP2008061849 2008-03-11
JP2008-199912 2008-08-01
JP2008199912 2008-08-01

Publications (2)

Publication Number Publication Date
WO2009113704A2 WO2009113704A2 (fr) 2009-09-17
WO2009113704A3 true WO2009113704A3 (fr) 2010-04-15

Family

ID=40952624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/054984 WO2009113704A2 (fr) 2008-03-11 2009-03-10 Composé contenant du fluor et procédé de détection de biomplécule l'utilisant

Country Status (2)

Country Link
JP (1) JP5676853B2 (fr)
WO (1) WO2009113704A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927732B2 (en) * 2012-03-30 2015-01-06 General Electric Company Biotin stannane for HPLC-free radioiodination

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592306A2 (fr) * 1992-10-06 1994-04-13 Terumo Kabushiki Kaisha Milieu de contraste pour 19F-MRI
US5690909A (en) * 1993-05-24 1997-11-25 Schering Aktiengesellschaft Fluorine-containing macrocyclic metal complexes
JPH1067728A (ja) * 1996-04-18 1998-03-10 Mitsubishi Chem Corp 含フッ素糖誘導体
WO2003045441A1 (fr) * 2001-11-28 2003-06-05 Amersham Health As Agents de contraste dans la detection in vivo de l'activite enzymatique
US20060047126A1 (en) * 2004-08-20 2006-03-02 Georg Gunda I Lonidamine analogues and their use in male contraception and cancer treatment
EP1916255A2 (fr) * 2006-09-19 2008-04-30 FUJIFILM Corporation Composant comportant un groupe alkyl à fluorine de substitution et support de constraste liposomale comportant le composant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
JP5172188B2 (ja) * 2007-03-28 2013-03-27 富士フイルム株式会社 フッ素置換アルキル基を有するグリセリド化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0592306A2 (fr) * 1992-10-06 1994-04-13 Terumo Kabushiki Kaisha Milieu de contraste pour 19F-MRI
US5690909A (en) * 1993-05-24 1997-11-25 Schering Aktiengesellschaft Fluorine-containing macrocyclic metal complexes
JPH1067728A (ja) * 1996-04-18 1998-03-10 Mitsubishi Chem Corp 含フッ素糖誘導体
WO2003045441A1 (fr) * 2001-11-28 2003-06-05 Amersham Health As Agents de contraste dans la detection in vivo de l'activite enzymatique
US20060047126A1 (en) * 2004-08-20 2006-03-02 Georg Gunda I Lonidamine analogues and their use in male contraception and cancer treatment
EP1916255A2 (fr) * 2006-09-19 2008-04-30 FUJIFILM Corporation Composant comportant un groupe alkyl à fluorine de substitution et support de constraste liposomale comportant le composant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CURRAN DENNIS P ET AL: "Synthesis and reactions of fluorous carbobenzyloxy (FCbz) derivatives of alpha-amino acids.", JOURNAL OF ORGANIC CHEMISTRY, vol. 68, no. 12, 13 June 2003 (2003-06-13), pages 4643 - 4647, XP002569627, ISSN: 0022-3263 *
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 12 October 2006 (2006-10-12), FLIPO M. ET AL: "A library of novel hydroxamic acids targeting the mettalo-protease family: Design, parallel synthesis and screening", XP002569646, Database accession no. 10584330 *
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 19 November 1996 (1996-11-19), XP002569629, Database accession no. 5788690 *
DOYON J B ET AL: "The pattern of fluorine substitution affects binding affinity in a small library of fluoroaromatic inhibitors for carbonic anhydrase.", ORGANIC LETTERS 29 JUL 1999, vol. 1, no. 2, 29 July 1999 (1999-07-29), pages 183 - 185, XP002569645, ISSN: 1523-7060 *
OISHI MOTOI ET AL: "On-off regulation of F-19 magnetic resonance signals based on pH-Sensitive PEGylated nanogels for potential tumor-specific smart F-19 MRI probes", BIOCONJUGATE CHEMISTRY, vol. 18, no. 5, September 2007 (2007-09-01), pages 1379 - 1382, XP002569683, ISSN: 1043-1802 *
YAMAZAKI K ET AL: "Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure", BIOORGANIC AND MEDICINAL CHEMISTRY 20050401 GB, vol. 13, no. 7, 1 April 2005 (2005-04-01), pages 2509 - 2522, XP004777464, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
JP2010053116A (ja) 2010-03-11
JP5676853B2 (ja) 2015-02-25
WO2009113704A2 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
MA31884B1 (fr) Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3
WO2008102678A1 (fr) Dérivé de pyrazole-carbonitrile contenant du fluor et son procédé de production, et dérivé de l'acide pyrazole-carboxylique contenant du fluor obtenu à l'aide du dérivé de pyrazole-carbonitrile contenant du fluor et son procédé de production
TW200641539A (en) Salt suitable for an acid generator and a chemically amplified resist composition containing the same
DE502006006388D1 (de) Organosiliciumverbindungen, ihre Herstellung und ihre Verwendung
WO2009146218A8 (fr) Composés comprenant un pharmacore anti-inflammatoire et procédés d'utilisation
WO2009054497A1 (fr) Nouveau composé présentant une affinité pour l'amyloïde
NO20081101L (no) Regioselektiv metode for fremstilling av benzimidazol-tiofener
EA201100051A1 (ru) Фторсодержащие простые эфиры силанов и способы их использования
WO2010009191A3 (fr) Composés d’éther fluorés et leurs procédés d’utilisation
WO2008126804A1 (fr) Composition destinée à former un film sous résist
JP2010501678A5 (fr)
NZ592382A (en) Thioamide compounds, method of making and method of using thereof
WO2010080353A3 (fr) Procédé de mise en contact de formations portant des hydrocarbures avec des compositions de phosphate et phosphonate fluorés
DK2537533T3 (da) Antitumor-biokonjugater af hyaluronsyre eller derivater deraf opnået ved indirekte kemisk konjugation
WO2009147031A3 (fr) Photoinitiateurs esters d'oximes
WO2010075263A3 (fr) Composés et méthode d'amplification de l'érythropoïèse
WO2008103489A3 (fr) Composés de ciblage d'arn, et procédés de fabrication et d'utilisation de ceux-ci
NO20075904L (no) Benzimidazolforbindelser
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
UY31013A1 (es) Metodos para prepar compuestos basados en imidazol
WO2009113704A3 (fr) Composé contenant du fluor et procédé de détection de biomplécule l'utilisant
WO2006050169A3 (fr) Mesure de parametres environnementaux
WO2007004177A3 (fr) Procede servant a mesurer des tranchees profondes au moyen d'une technique de spectroscopie optique basee modele
DE102004017026A1 (de) Ionische Flüssigkeiten mit Fluoralkyltrifluorborat-Anionen
WO2009081151A3 (fr) Procédés de modification d'un peptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09720666

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09720666

Country of ref document: EP

Kind code of ref document: A2